Subdividing those counselees according to receptor status, invasiveness and gender, the majority of 70.8% (n = 533) had hormone receptor positive and/or HER2-amplified breast cancer and a relevant part of 23.5% (n = 177) had triple-negative breast cancer, whereas ductal carcinoma in situ (n = 39; 5.2%) and male breast cancer (n = 4; 0.5%) were less common. Here, ERBB2 is linked to triple-negative breast carcinoma.